O

Option Care Health

Largest independent home infusion therapy provider

Patient Scheduler

Full-TimeUpdated
$21.47 - $31.20
Junior
Riverside, CA, USA
In Person
Medical, Clinical & VeterinaryClinical Support & Patient Administration

About the job

Requirements
  • A high school diploma or equivalent is required.
  • At least 1 year of previous scheduling experience is required.
  • At least 1 year of experience in a general office administration setting or a similar fast-paced environment is required.
  • Experience communicating verbally by phone, one-on-one, and to groups, and in writing through emails, letters, and reports, to work groups, teams, company management, and external clients is required.
  • Basic-level skill in Microsoft Word 2003 or later is required, including creating documents, entering and formatting text, page layouts, creating tables, and adding graphics.
  • Basic-level skill in Microsoft Excel 2003 or later is required, including creating worksheets, entering data, creating basic formulas, and working with cells and rows.
  • Experience providing customer service to internal and external customers, including meeting service quality standards and evaluating customer satisfaction, is required.
Responsibilities
  • Ensure appropriate staffing is arranged for all patient care.
  • Coordinate, monitor, and schedule patient care across all clinical areas.
  • Contact patients and clinicians to schedule and confirm deliveries and visits.
  • Interpret physician’s orders and schedule according to those orders.
  • Complete tasks and run reports in required platforms.
  • Coordinate scheduling needs with staffing availability.
  • Ensure management is aware of staffing needs and requirements.
  • Facilitate patient complaints or issues to the appropriate department.
  • Perform clerk functions in addition to scheduling functions when a clerk is absent, if needed.
  • Observe legal and ethical guidelines for safeguarding the confidentiality of patient and proprietary company information.
  • Accept other responsibilities and duties as assigned.
Desired Qualifications
  • Previous home healthcare experience.
  • Familiarity with an electronic scheduling platform.
  • Two years of experience in a general office administration setting or a similar fast-paced environment.

About the company

Option Care Health delivers infusion therapies at home and other alternate-site locations across the United States, supported by over 7,000 teammates including about 4,500 clinicians. Clinicians visit patients at home or approved sites to administer therapies, manage care, and coordinate with care teams under strong clinical leadership and national scale. It stands out as the largest independent infusion provider with nationwide reach and a robust clinical workforce, enabling scalable home and alternate-site infusion rather than hospital-only care. The goal is to elevate standards of care and reimagine the infusion care experience by expanding access, improving outcomes, and delivering compassionate, clinically driven service.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Bannockburn, Illinois

Founded

1979

Get referred to Option Care Health

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 29, 2026 Q2 revenue reached $1.44 billion, while acute therapy and IG Neuro strengthened.
  • Management stabilized CID patient census in Q2 2026 and kept full-year revenue guidance unchanged.
  • The company repurchased $150 million in Q2 2026, signaling confidence and shareholder-return capacity.

What critics are saying

  • August 2026 guidance still bakes in a 600-basis-point CID revenue headwind and $55 million gross profit hit.
  • July 29, 2026 Q2 buyback of $150 million masks weak top-line momentum and analyst skepticism.
  • Biosimilar erosion and payer reverification pressure can permanently shrink chronic volumes if retention stays broken.

What makes Option Care Health unique

  • Option Care Health leads U.S. independent home and alternate-site infusion, with nationwide clinician density.
  • Its payer, biopharma, and prescriber relationships create switching costs across chronic and acute therapies.
  • August 27, 2026 guidance shows durable cash generation, with at least $320 million operating cash flow.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Paid Time Off
  • Bonding Time Off
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Health Savings Account/Flexible Spending Account
  • Flexible Spending Accounts
  • Tuition Reimbursement
  • Family Support
  • Mental Health Support

Company News

American Market News
Oct 23rd, 2026
Option Care Health, Inc. $OPCH holdings increased by Isthmus Partners LLC.

Option Care Health, Inc. $OPCH holdings increased by Isthmus Partners LLC. Posted by ABMN Staff on Oct 23rd, 2026 Isthmus Partners LLC boosted its stake in Option Care Health, Inc. (NASDAQ:OPCH - Free Report) by 37.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 169,172 shares of the company's stock after acquiring an additional 46,518 shares during the period. Isthmus Partners LLC owned 0.11% of Option Care Health worth $3,805,000 at the end of the most recent reporting period. A number of other hedge funds have also added to or reduced their stakes in the stock. Reyes Financial Architecture Inc. purchased a new position in shares of Option Care Health during the third quarter valued at about $28,000. Pinnacle Associates Ltd. lifted its holdings in Option Care Health by 1.8% in the third quarter. Pinnacle Associates Ltd. now owns 20,355 shares of the company's stock worth $458,000 after buying an additional 354 shares during the period. Nisa Investment Advisors LLC boosted its position in Option Care Health by 268.9% during the 3rd quarter. Nisa Investment Advisors LLC now owns 2,955 shares of the company's stock valued at $66,000 after acquiring an additional 2,154 shares in the last quarter. Fort Washington Investment Advisors Inc. OH grew its holdings in shares of Option Care Health by 5.1% during the 3rd quarter. Fort Washington Investment Advisors Inc. OH now owns 1,421,567 shares of the company's stock worth $31,971,000 after acquiring an additional 68,572 shares during the period. Finally, Central Pacific Bank Trust Division grew its holdings in shares of Option Care Health by 3.9% during the 3rd quarter. Central Pacific Bank Trust Division now owns 14,369 shares of the company's stock worth $323,000 after acquiring an additional 540 shares during the period. 98.05% of the stock is owned by hedge funds and other institutional investors. Option Care Health stock performance. Shares of Option Care Health stock opened at $31.29 on Friday. The business has a 50-day moving average of $25.57 and a 200 day moving average of $23.84. Option Care Health, Inc. has a 12 month low of $18.01 and a 12 month high of $36.80. The stock has a market capitalization of $4.69 billion, a price-to-earnings ratio of 19.80, a price-to-earnings-growth ratio of 1.90 and a beta of 0.58. The company has a debt-to-equity ratio of 0.91, a current ratio of 1.47 and a quick ratio of 0.98. Discover more Read Daily News Option Care Health (NASDAQ:OPCH - Get Free Report) last released its earnings results on Wednesday, July 29th. The company reported $0.45 earnings per share for the quarter, beating the consensus estimate of $0.43 by $0.02. The company had revenue of $1.44 billion during the quarter, compared to the consensus estimate of $1.42 billion. Option Care Health had a return on equity of 18.74% and a net margin of 3.68%. Option Care Health's revenue was up 1.9% compared to the same quarter last year. During the same period in the previous year, the company posted $0.41 EPS. Option Care Health has set its FY 2026 guidance at 1.850-1.920 EPS. As a group, sell-side analysts forecast that Option Care Health, Inc. will post 1.70 earnings per share for the current year. Wall street analysts forecast growth. Several brokerages have recently issued reports on OPCH. Jefferies Financial Group lowered Option Care Health from a "buy" rating to a "hold" rating and increased their target price for the stock from $28.00 to $32.05 in a research report on Tuesday, October 6th. Barrington Research lowered shares of Option Care Health from an "outperform" rating to a "hold" rating in a research report on Wednesday, October 7th. UBS Group lowered Option Care Health from a "buy" rating to a "neutral" rating and dropped their target price for the company from $39.00 to $32.05 in a research report on Friday, October 9th. Morgan Stanley set a $32.05 price target on shares of Option Care Health in a research report on Monday, October 12th. Finally, JPMorgan Chase & Co. reaffirmed a "neutral" rating and issued a $33.00 price target on shares of Option Care Health in a research note on Wednesday, October 7th. Two investment analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, Option Care Health presently has an average rating of "Hold" and an average price target of $29.48. About Option Care Health. Option Care Health, Inc is an independent provider of home and alternate-site infusion services in the United States. The company coordinates and delivers infusion therapy outside traditional hospital settings, including patients' homes, ambulatory infusion suites and other outpatient locations. Its services include administration of anti-infective therapies, immune globulin, nutrition support, inotropic therapies and medications used in the treatment of chronic and complex conditions. Want to see what other hedge funds are holding OPCH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Option Care Health, Inc. (NASDAQ:OPCH - Free Report). Receive News & Ratings for Option Care Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Option Care Health and related companies with MarketBeat.com's FREE daily email newsletter.

AD HOC NEWS
Oct 15th, 2026
McKesson commits $1.4B for 49% stake in Option Care at $5.8B valuation

McKesson will invest $1.4 billion for a 49% minority stake in Option Care Health, under an agreement announced on October 6, 2026. The deal values Option Care at an enterprise value of $5.8 billion. Clayton, Dubilier & Rice will hold about 51%. Option Care will stay separately managed, while McKesson keeps a framework to acquire the remaining interest later, subject to conditions and regulatory approvals. In its first fiscal 2027 quarter, McKesson reported revenue of $105.38 billion, up 7.7% year on year, and adjusted earnings per share of $9.93. It will report second-quarter results on November 4, 2026.

Yahoo Finance
Oct 6th, 2026
McKesson and Clayton Dubilier & Rice near $5B deal to acquire Option Care Health

Option Care Health shares jumped 33.2% in pre-market trading after the Financial Times reported McKesson and Clayton Dubilier & Rice are nearing a transaction valued at over $5 billion to acquire the alternate site health provider. According to the report, the deal would involve the two firms partnering to buy the infusion services provider, which they view as undervalued. Large-scale buyout discussions typically drive market optimism as investors anticipate acquisition premiums. The move is significant for Option Care Health, whose shares have experienced 13 movements greater than 5% over the past year. At $31.03 per share, the stock is trading 15.2% below its 52-week high but remains down 3.8% year-to-date.

Central Charts
Oct 6th, 2026
CD&R and McKesson Corporation Sign Agreement to Acquire Option Care Health

CD&R, McKesson Corporation (NYSE: MCK) (“McKesson”), and Option Care Health, Inc. (Nasdaq: OPCH) (“Option Care Health”) announced today that they have

Yahoo Finance
Jul 29th, 2026
Option Care Health Q2 beats expectations with $1.4B revenue, narrows full-year guidance

Option Care Health reported second-quarter 2026 results that exceeded expectations. Revenue rose 7% sequentially to $1.4 billion, whilst adjusted EBITDA increased 12% to $117.5 million and adjusted EPS reached $0.45. Operating cash flow totalled $184 million. Acute therapies posted high-single-digit organic growth, while chronic revenue improved sequentially as the CID portfolio began to stabilise. However, CID-related pressure is expected to reduce 2026 revenue by roughly 600 basis points and gross profit by $55 million. The home and alternate-site infusion provider maintained its full-year revenue guidance at $5.675 billion to $5.775 billion. Adjusted EBITDA guidance was narrowed to $480 million to $495 million, and adjusted EPS guidance to $1.85 to $1.92. The company repurchased $150 million of shares, nearly 5% of shares outstanding.